Sensor and software use for the glycaemic management of insulin-treated type 1 and type 2 diabetes patients
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Lowering glucose levels, while avoiding hypoglycaemia, can be challenging in insulin-treated patients with diabetes. We evaluated the role of ambulatory glucose profile in optimising glycaemic control in this population. Insulin-treated patients with type 1 and type 2 diabetes were recruited into a prospective, multicentre, 100-day study and randomised to control ( n = 28) or intervention ( n = 59) groups. The intervention group used ambulatory glucose profile, generated by continuous glucose monitoring, to assess daily glucose levels, whereas the controls relied on capillary glucose testing. Patients were reviewed at days 30 and 45 by the health care professional to adjust insulin therapy. Comparing first and last 2 weeks of the study, ambulatory glucose profile–monitored type 2 diabetes patients ( n = 28) showed increased time in euglycaemia (mean ± standard deviation) by 1.4 ± 3.5 h/day ( p = 0.0427) associated with reduction in HbA 1c from 77 ± 15 to 67 ± 13 mmol/mol ( p = 0.0002) without increased hypoglycaemia. Type 1 diabetes patients ( n = 25) showed reduction in hypoglycaemia from 1.4 ± 1.7 to 0.8 ± 0.8 h/day ( p = 0.0472) associated with a marginal HbA 1c decrease from 75 ± 10 to 72 ± 8 mmol/mol ( p = 0.0508). Largely similar findings were observed comparing intervention and control groups at end of study. In conclusion, ambulatory glucose profile helps glycaemic management in insulin-treated diabetes patients by increasing time spent in euglycaemia and decreasing HbA 1c in type 2 diabetes patients, while reducing hypoglycaemia in type 1 diabetes patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Continuous glucose monitoring and intensive treatment of type 1 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0805017 · Cited by 1,559
Ismail-Beigi, F., Craven, T., Banerji, M. A., Basile, J., Calles, J., Cohen, R. M., Cuddihy, R., Cushman, W. C., Genuth, S., Grimm, R. H., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60576-4 · Cited by 1,428
Effectiveness of Sensor-Augmented Insulin-Pump Therapy in Type 1 Diabetes
Bergenstal, R. M., Tamborlane, W. V., Ahmann, A., Buse, J. B., Dailey, G., Davis, S. N., Joyce, C., Peoples, T., Perkins, B. A., Welsh, J. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002853 · Cited by 894
Pickup, J. C., Freeman, S. C., & Sutton, A. J. (2011) · BMJ · doi:10.1136/bmj.d3805 · Cited by 541
Deiss, D., Bolinder, J., Riveline, J.-P., Battelino, T., Bosi, E., Tubiana-Rufi, N., Kerr, D., & Phillip, M. (2006) · Diabetes Care · doi:10.2337/dc06-1134 · Cited by 539
the SWITCH Study Group, Battelino, T., Conget, I., Olsen, B., Schütz-Fuhrmann, I., Hommel, E., Hoogma, R., Schierloh, U., Sulli, N., & Bolinder, J. (2012) · Diabetologia · doi:10.1007/s00125-012-2708-9 · Cited by 494
Not Available, N. A. (1998) · Diabetologia · doi:10.1007/s001250050924 · Cited by 308
Yoo, H. J., An, H. G., Park, S. Y., Ryu, O. H., Kim, H. Y., Seo, J. A., Hong, E. G., Shin, D. H., Kim, Y. H., Kim, S. G., et al. (2008) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2008.06.015 · Cited by 244
Ehrhardt, N. M., Chellappa, M., Walker, M. S., Fonda, S. J., & Vigersky, R. A. (2011) · Journal of Diabetes Science and Technology · doi:10.1177/193229681100500320 · Cited by 199
Poolsup, N., Suksomboon, N., & Kyaw, A. M. (2013) · Diabetology & Metabolic Syndrome · doi:10.1186/1758-5996-5-39 · Cited by 179
Cited by
Grunberger, G., Sherr, J., Allende, M., Blevins, T., Bode, B., Handelsman, Y., Hellman, R., Lajara, R., Roberts, V. L., Rodbard, D., et al. (2021) · Endocrine Practice · doi:10.1016/j.eprac.2021.04.008 · Cited by 288
Teo, E., Hassan, N., Tam, W., & Koh, S. (2022) · Diabetologia · doi:10.1007/s00125-021-05648-4 · Cited by 186
Seidu, S., Kunutsor, S. K., Ajjan, R. A., & Choudhary, P. (2024) · Diabetes Care · doi:10.2337/dc23-1520 · Cited by 124
Self-citationZahedani, A. D., McLaughlin, T., Veluvali, A., Aghaeepour, N., Hosseinian, A., Agarwal, S., Ruan, J., Tripathi, S., Woodward, M., Hashemi, N., et al. (2023) · npj Digital Medicine · doi:10.1038/s41746-023-00956-y · Cited by 96
“Continuous glucose monitors (CGM) are wearables that, via alarm features and real-time feedback to the user about glucose trends, were initially shown to lower both hyper and hypoglycemia in T1D and multidose-insulin-treated T2D 20 – 27 .”
Kröger, J., Fasching, P., & Hanaire, H. (2020) · Diabetes Therapy · doi:10.1007/s13300-019-00741-9 · Cited by 90
Metadata
- Authors
- Ajjan, R. A., Abougila, K., Bellary, S., Collier, A., Franke, B., Jude, E. B., Rayman, G., Robinson, A., & Singh, B. M.
- Venue
- Diabetes and Vascular Disease Research
- Publisher
- SAGE Publications
- Published
- 2016-03-21
- Volume
- 13
- Issue
- 3
- Pages
- 211-219
- ISSN
- 1479-1641 (ISSN-L)
- 1752-8984
- OpenAlex
- W2334585085
- Cited by
- 30
- References
- 11
- FWCI
- 2.89
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Sensor and software use for the glycaemic management of insulin-treated type 1 and type 2 diabetes patients. https://app.cochat.ai/papers/10.1177/1479164115624680
- The paper
- Ajjan, R. A., Abougila, K., Bellary, S., Collier, A., Franke, B., Jude, E. B., Rayman, G., Robinson, A., & Singh, B. M. (2016). Sensor and software use for the glycaemic management of insulin-treated type 1 and type 2 diabetes patients. Diabetes and Vascular Disease Research. https://doi.org/10.1177/1479164115624680
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.